AKTX Valuation - Is Akari Therapeutics Plc Over or Undervalued?

Comprehensive analysis of Akari Therapeutics Plc valuation metrics including P/E, P/B, P/S, and EV/EBITDA ratios

Updated March 19, 2026-6 min read-View Full Analysis

Current Stock Price

$0.16

Market Cap

$0.02B

Valuation Date

Mar 19, 2026

Valuation Verdict

Potentially Undervalued

Based on valuation multiples, AKTX appears attractively priced. 1 key metrics suggest potential value opportunity.

Key Valuation Metrics

These four fundamental valuation ratios help determine if AKTX is trading at a fair price relative to its earnings, assets, revenue, and cash flow generation.

P/E Ratio (Price-to-Earnings)

N/A

Not profitable or data unavailable

P/B Ratio (Price-to-Book)

Good

0.44x

Trading below book value

Stock trades at 0.44x its book value per share

P/S Ratio (Price-to-Sales)

N/A

Revenue data unavailable

EV/EBITDA

N/A

EBITDA data unavailable

How to Interpret These Metrics

P/E Ratio: Lower P/E often indicates better value, but compare against industry peers. High-growth companies typically have higher P/E ratios. Market average is 15-20x.

P/B Ratio: Values below 1.0 suggest the stock trades below its net asset value, which could indicate undervaluation or fundamental problems. Technology companies often trade at higher P/B ratios.

P/S Ratio: Useful for unprofitable companies or comparing revenue efficiency. Lower is generally better, but high-margin businesses can justify higher P/S ratios.

EV/EBITDA: Accounts for debt and excludes non-cash expenses, making it ideal for comparing companies with different capital structures. Values under 10x often indicate good value.

How AKTX Compares to Peers

What This Means for Investors

Potential Value Opportunity

Akari Therapeutics Plc (AKTX) currently trades at valuation multiples that appear attractive relative to historical averages and peer comparisons. This could represent a buying opportunity for long-term investors who believe in the company's fundamentals. However, always investigate why the market is pricing the stock this way - there may be legitimate concerns about future growth or profitability.

Bullish Considerations

Reasonable price relative to book value
Multiple metrics suggest undervaluation

Bearish Considerations

Complete Your Analysis

Valuation is just one piece of the puzzle. Get the complete picture of AKTX with our comprehensive analysis tools.

Full Stock Analysis

Complete financials, charts, and metrics

Should I Buy AKTX?

AI-powered investment recommendation

Price Forecast

Future price targets and predictions

Analyst Ratings

Wall Street consensus and targets

Deep Valuation Analysis

DCF model and intrinsic value

Frequently Asked Questions

What is AKTX's P/E ratio and what does it mean?

AKTX has a P/E (Price-to-Earnings) ratio of N/A. This means investors are paying $N/A for every $1 of annual earnings. A lower P/E generally suggests better value, but it's important to compare against industry peers and growth prospects. The market average P/E is typically 15-20x.

Is AKTX stock overvalued or undervalued?

Based on our analysis of key valuation metrics (P/E, P/B, P/S, EV/EBITDA), AKTX appears potentially undervalued. Based on valuation multiples, AKTX appears attractively priced. 1 key metrics suggest potential value opportunity. However, valuation is just one factor to consider alongside growth prospects, competitive position, and market conditions.

What is a good P/E ratio for AKTX?

There's no single "good" P/E ratio as it varies by industry and growth stage. For Akari Therapeutics Plc, compare the current P/E of N/A against: (1) Industry peers, (2) Historical average P/E for AKTX, (3) Expected earnings growth rate. High-growth companies often justify higher P/E ratios, while mature companies typically trade at lower multiples.

How do I use valuation ratios to make investment decisions?

Valuation ratios are screening tools, not buy/sell signals. Use them to: (1) Compare AKTX against competitors, (2) Identify potential over/undervaluation, (3) Understand what you're paying for earnings, assets, or sales. Combine valuation analysis with fundamental research, growth prospects, and technical analysis for comprehensive decision-making.

What is EV/EBITDA and why does it matter?

EV/EBITDA (Enterprise Value to EBITDA) is N/A for AKTX. This ratio is useful because it accounts for debt and excludes non-cash expenses, making it better for comparing companies with different capital structures. Lower EV/EBITDA generally indicates better value. It's particularly useful for comparing companies in capital-intensive industries.

Disclaimer: This valuation analysis is for informational and educational purposes only and should not be considered investment advice. Valuation metrics are just one factor in investment decisions. Always conduct comprehensive research and consult with a qualified financial advisor before making investment decisions. Past performance and current valuations do not guarantee future results.